DDIT3 and mature T-cell and NK-cell non-Hodgkin lymphoma: Preclinical work in PTCL suggested a combinational effect on cell death in PTCL in tumor models when lacutamab was used with cytotoxic agents, either CHOP or pralatrexate [254].